Pharmaceuticals, Biotechnology and Life Sciences
TOKYO and CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and…
LOS ANGELES, July 30, 2025 (GLOBE NEWSWIRE) — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for…
– ABO-101 was well tolerated with no serious adverse events or dose-limiting toxicities reported in the 28-days following dosing –…
MELBOURNE, Australia and INDIANAPOLIS, July 30, 2025 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises…
VANCOUVER, British Columbia, July 29, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSXV: RKV) (FSE: 7JO0) (the “Company” or “Rakovina”),…
Châtillon, France, July 29, 2025 DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the…
DURHAM, N.C., July 29, 2025 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in…
Châtillon, France, July 29, 2025 DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results DBV Technologies (Euronext: DBV –…
– Trial demonstrates 49% confirmed ORR in the 30mg onvansertib dose arm versus 30% confirmed ORR in the control arm…
SALT LAKE CITY, July 29, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing…